|
Feb 12
|
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
|
|
Feb 11
|
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
|
|
Feb 10
|
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
|
|
Feb 10
|
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
|
|
Oct 14
|
Astella’s iota receives FDA go-ahead for bladder implant trial
|
|
Oct 10
|
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
|
|
Oct 10
|
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
|
|
Jul 26
|
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
|
|
Jul 26
|
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
|
|
May 13
|
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
|
|
May 8
|
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
|
|
Mar 22
|
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
|
|
Mar 20
|
Q4 2023 Taysha Gene Therapies Inc Earnings Call
|
|
Mar 19
|
With new data, Bayer readies rival to Astellas menopause drug
|
|
Jan 8
|
US FDA declines to approve Astellas' gastric cancer drug
|
|
Jan 8
|
Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
|
|
Dec 28
|
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
|
|
Dec 21
|
Astellas Completes Acquisition of Propella Therapeutics
|
|
Dec 15
|
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
|
|
Dec 15
|
UPDATE 2-US FDA approves Astellas' combination therapy for bladder cancer
|